Search
Cytek Biosciences Inc
CTKBAdd to Watchlist
4.220USD
-0.090-2.09%
Close 07-31 16:00（ET）Quotes delayed by 15 min
544.98MMarket Cap
LossP/E TTM
More Details of Cytek Biosciences Inc Company
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
Cytek Biosciences Inc Info
Ticker SymbolCTKB
Company nameCytek Biosciences Inc
IPO dateJul 23, 2021
CEOJiang (Wenbin)
Number of employees648
Security typeOrdinary Share
Fiscal year-endJul 23
Address47215 Lakeview Boulevard
CityFREMONT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94538
Phone18779229835
Websitehttps://cytekbio.com
Ticker SymbolCTKB
IPO dateJul 23, 2021
CEOJiang (Wenbin)
Company Executives of Cytek Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.48M
+1.00%
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
4.80M
-2.83%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
150.01K
+10.38%
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
60.69K
+72.45%
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
59.68K
+73.68%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
59.68K
+73.68%
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.48M
+1.00%
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
4.80M
-2.83%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
150.01K
+10.38%
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
60.69K
+72.45%
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
59.68K
+73.68%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
59.68K
+73.68%
FAQs
Who are the top five shareholders of Cytek Biosciences Inc?
The top five shareholders of Cytek Biosciences Inc are: Dr. Wenbin Jiang, Ph.D.
How many institutions hold shares of Cytek Biosciences Inc (CTKB)?
As of 2026Q1, 335 institutions hold shares of Cytek Biosciences Inc, with a combined market value of approximately 84.13M, accounting for 65.16% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -7060937.00.
What is the biggest source of revenue for Cytek Biosciences Inc?
In 2026Q1, the Biotechnology, pharmaceutical, distributor and CRO business generated the highest revenue for Cytek Biosciences Inc, amounting to 116.73M and accounting for 57.93% of total revenue.